US 3rd Quarter Shows Growth Despite Pressures
The first US pharmaceutical companies to post financial results for the third-quarter and nine-month periods of 1994 have revealed strong growth despite the pressures that the pharmaceutical industry is currently experiencing.
- Amgen's sales of its two lead products Neupogen (filgrastim) and Epogen (epoetin alfa) were strong. Neupogen sales advanced 15% in the third quarter of 1994 to $215 million. In the USA sales of the product grew 11% to $160 million, and international sales soared 29% to $54.6 million. Epogen sales in the third quarter were $187 million, up 25%.
Gordon Binder, chairman and chief executive, said: "I am confident that the strong patient benefits of Epogen and Neupogen will enable us to achieve double-digit sales and earnings growth in 1995 and that these breakthrough products, as well as others being explored through in-house discovery and external collaboration, will continue to fuel growth in later years."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze